



Influenza Work Group—Introduction

Dr. Jamie Loehr (Work Group Chair)

Advisory Committee on Immunization Practices

February 28, 2024

Influenza Work Group

ACIP Members

- Jamie Loehr (Chair)
- Camille Kotton

Ex Officio

- Timothy Brennan (FDA)
- Uzo Chukwuma (IHS)
- Michael Ison (NIH)
- Jeffrey Kelman (CMS)
- Valerie Marshall (OASH)
- Cynthia Nolletti (FDA)
- Chris Roberts (NIH)

Liaison Representatives and Consultants

- Robert Atmar
- Kevin Ault
- Ed Belongia
- Hank Bernstein
- Thomas Boyce
- Kris Bryant
- Doug Campos-Outcalt
- Sarah Coles
- Dana Deshon
- Frances Ferguson
- Alicia Fry
- Sandra Fryhofer
- Wendy Keitel
- Marie-Michèle Léger
- Susan Lett
- Krissy Moehling
- Zackary Moore
- Rebecca Morgan
- Kathy Neuzil
- Jesse Papenburg
- William Schaffner
- Rob Schechter
- Ken Schmader
- Tamara Sheffield
- Angela Sinilaite
- Patsy Stinchfield
- Peter Szilagyi
- Keipp Talbot
- Matthew Zahn

CDC Lead

- Lisa Grohskopf

CDC Participants

- Lenee Blanton
- Karen Broder
- Alicia Budd
- Jessie Chung
- Sascha Ellington
- Jill Ferdinands
- Brendan Flannery
- Andrew Kroger
- Samantha Olson
- David Shay
- Tom Shimabukuro
- Mark Tenforde
- Tim Uyeki

Influenza Vaccine Effectiveness (VE) Estimates

Issue:

- Influenza vaccine effectiveness varies and is assessed annually through several CDC platforms focusing on laboratory-confirmed influenza outpatient visits and hospitalizations in adult and pediatric populations.
- VE estimates are presented to the ACIP as they become available.
- Preliminary 2023-24 VE estimates are available from CDC platforms and from a study performed by the California Department of Public Health.

Updates:

- ***Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness***
 - *Dr. Aaron Frutos (CDC/NCIRD/ID)*
- ***Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza in California, October 2023—January 2024***
 - *Dr. Sophie Zhu (California Department of Public Health and CDC/PHIC/DWD)*

Live Attenuated Influenza Vaccine (LAIV) in Setting of Asthma/Wheezing

Issue:

- In current ACIP recommendations, LAIV (licensed for ages 2 through 49 years) is not recommended for children ages 2 through 4 years with a history of asthma or wheezing.
 - Based on early studies suggesting potential increased risk of wheezing following LAIV in young children.
- Asthma in persons ages 5 years and older is considered a precaution for LAIV.

Updates:

- ***Safety of LAIV4 in Children with Asthma***
 - *Dr. C. Buddy Creech, Vanderbilt University Medical Center*

Influenza B/Yamagata and Influenza Vaccine Composition

Issue:

- Current U.S. influenza vaccines are quadrivalent, containing hemagglutinin antigen derived from four influenza viruses: A(H1N1pdm09), A(H3N2), B/Victoria, and B/Yamagata.
- As discussed at the October 2023 ACIP meeting, there have been no confirmed detections of influenza B/Yamagata lineage viruses in global surveillance since March 2020.
- WHO and the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) have recommended exclusion of the B/Yamagata component from influenza vaccines as soon as possible.

Update:

- ***Influenza B/Yamagata Update***
 - *Dr. Lisa Grohskopf (CDC/NCIRD/ID)*

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

